Last reviewed · How we verify

DBI-002 Gel — Competitive Intelligence Brief

DBI-002 Gel (DBI-002 Gel) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Skin microbiome modulator. Area: Dermatology.

phase 2 Skin microbiome modulator Dermatology Biologic Live · refreshed every 30 min

Target snapshot

DBI-002 Gel (DBI-002 Gel) — DermBiont, Inc.. DBI-002 Gel is a topical treatment that modulates the skin microbiome to improve symptoms of atopic dermatitis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DBI-002 Gel TARGET DBI-002 Gel DermBiont, Inc. phase 2 Skin microbiome modulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Skin microbiome modulator class)

  1. DermBiont, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DBI-002 Gel — Competitive Intelligence Brief. https://druglandscape.com/ci/dbi-002-gel. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing